Projected Tumor Characteristics and Survival of Patients with Nonviral Hepatocellular Carcinoma in the USA
Digestive Diseases · 2025
DOI: 10.1159/000546600 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive Diseases, 2025. Verfasst von Joanne Kimiko Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto, California, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Nonviral liver diseases, including alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD), are increasing the burden of nonviral hepatocellular carcinoma (HCC) in the USA. We aimed to model and project the demographic and tumor characteristics and survival of individuals with nonviral HCC in the USA.
Methods
We performed a cohort study using the linked Surveillance, Epidemiology, and End Results Program (SEER) and Medicare enrollment database (2000–2017). Of 78,431 adult Medicare beneficiaries with HCC, we excluded patients with a nonprimary liver tumor, HCC diagnosis before Medicare coverage started, and without a primary liver disease etiology of MASLD or ALD. We used linear regression to model changes in demographic and tumor characteristics and survival of patients with nonviral HCC and applied this model to describe future trends up to 2035.
Results
In our cohort of 23,926 patients with nonviral HCC (18,266 with MASLD and 5,660 with ALD), the mean age at diagnosis between 2000 and 2017 was 73 years and 68–69% were male. Though we projected increasing trends for survival, both median (1.31 years [95% CI: 1.22–1.41] in 2035) and 5-year survival rates (22.0% [95% CI: 19.9–24.2] in 2027) are expected to remain low. We projected that by 2027, 1/3 of patients will be diagnosed with stage III or IV tumors, and by 2030, more than 1/3 of HCC diagnoses will be of multifocal and metastatic tumors.
Conclusion
Focused efforts are needed to expand the use and effectiveness of HCC screening to improve the early detection and survival outcomes of HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto, California, USA.
- Division of Oncology, Department of Medicine, Stanford University Medical Center, Palo Alto, California, USA.
- Department of Epidemiology and Population Health, Stanford University Medical Center, Palo Alto, California, USA.
- Stanford Cancer Institute, Stanford University Medical Center, Palo Alto, California, USA.
- Division of Gastroenterology and Hepatology, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA.
Zitieren
APA
Liu, J. K., Chien, N., Chong, C., Barnett, S., Henry, L., John, E. M., Cheung, R., & Nguyen, M. H. (2025). Projected Tumor Characteristics and Survival of Patients with Nonviral Hepatocellular Carcinoma in the USA. Digestive Diseases. https://doi.org/10.1159/000546600
Vancouver
Liu JK, Chien N, Chong C, Barnett S, Henry L, John EM, et al. Projected Tumor Characteristics and Survival of Patients with Nonviral Hepatocellular Carcinoma in the USA. Digestive Diseases. 2025. doi:10.1159/000546600
BibTeX
@article{Liu2025,
author = {Liu, Joanne Kimiko and Chien, Nicholas and Chong, Curtis and Barnett, Scott and Henry, Linda and John, Esther M and Cheung, Ramsey and Nguyen, Mindie H},
title = {Projected Tumor Characteristics and Survival of Patients with Nonviral Hepatocellular Carcinoma in the USA},
journal = {Digestive Diseases},
year = {2025},
doi = {10.1159/000546600}
}
EUVIMED